Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I study. (5th July 2017)